H
Hannah Maynard
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 9
Citations - 611
Hannah Maynard is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Cancer & Veliparib. The author has an hindex of 6, co-authored 8 publications receiving 413 citations. Previous affiliations of Hannah Maynard include Cornell University.
Papers
More filters
Journal ArticleDOI
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Maeve A. Lowery,Winston Wong,Emmet Jordan,Jonathan W. Lee,Yelena Kemel,Joseph Vijai,Diana Mandelker,Ahmet Zehir,Marinela Capanu,Erin E. Salo-Mullen,Angela G. Arnold,Kenneth H. Yu,Anna M. Varghese,David P. Kelsen,Robin Brenner,Erica S. Kaufmann,Vignesh Ravichandran,Semanti Mukherjee,Michael F. Berger,David M. Hyman,David S. Klimstra,Ghassan K. Abou-Alfa,Catherine Tjan,Christina M. Covington,Hannah Maynard,Peter J. Allen,Gokce Askan,Steven D. Leach,Christine A. Iacobuzio-Donahue,Mark E. Robson,Kenneth Offit,Zsofia K. Stadler,Eileen M. O'Reilly +32 more
TL;DR: Data support routinely offering GT in all pancreatic ductal adenocarcimona patients with a broad panel of known hereditary cancer predisposition genes, and suggest these PGAs are therapeutically actionable in about 5% to 10% of patients.
Journal ArticleDOI
Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype.
Maeve A. Lowery,Emmet Jordan,Olca Basturk,Ryan Ptashkin,Ahmet Zehir,Michael F. Berger,Tanisha Leach,Brian Herbst,Gokce Askan,Hannah Maynard,Danielle C. Glassman,Christina M. Covington,Nikolaus Schultz,Ghassan K. Abou-Alfa,Ghassan K. Abou-Alfa,James J. Harding,James J. Harding,David S. Klimstra,Jaclyn F. Hechtman,David M. Hyman,David M. Hyman,Peter J. Allen,Peter J. Allen,William R. Jarnagin,William R. Jarnagin,Vinod P. Balachandran,Vinod P. Balachandran,Anna M. Varghese,Mark A. Schattner,Kenneth H. Yu,Leonard B. Saltz,Leonard B. Saltz,David B. Solit,David B. Solit,Christine A. Iacobuzio-Donahue,Steven D. Leach,Eileen M. O'Reilly,Eileen M. O'Reilly +37 more
TL;DR: The practical application of molecular results to guide individual patient treatment is currently limited in patients with pancreatic adenocarcinoma, and future prospective molecular profiling efforts should seek to incorporate routine germline genetic analysis and the identification of DNA profiles that predict for clinical benefit from agents that target DNA damage repair and or immunotherapy.
Journal ArticleDOI
Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Maeve A. Lowery,David P. Kelsen,Marinela Capanu,Sloane C. Smith,Jonathan W. Lee,Zsofia K. Stadler,Malcolm J. Moore,Hedy L. Kindler,Talia Golan,Amiel Segal,Hannah Maynard,Ellen Hollywood,ME Moynahan,Erin E. Salo-Mullen,Richard K. G. Do,Alice P. Chen,Kenneth H. Yu,Laura H. Tang,Eileen M. O'Reilly,Eileen M. O'Reilly +19 more
TL;DR: Veliparib was well tolerated, but no confirmed response was observed although four patients remained on study with SD for ≥ 4 months, and ongoing trials are evaluating PARPis combined with chemotherapy and as a maintenance strategy.
Journal ArticleDOI
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
Eileen M. O'Reilly,Eileen M. O'Reilly,Jonathan W. Lee,Maeve A. Lowery,Marinela Capanu,Zsofia K. Stadler,Zsofia K. Stadler,Malcolm J. Moore,Neesha C. Dhani,Hedy L. Kindler,Hayley Estrella,Hannah Maynard,Talia Golan,Amiel Segal,Erin E. Salo-Mullen,Kenneth H. Yu,Kenneth H. Yu,Andrew S. Epstein,Andrew S. Epstein,Michal Segal,Robin Brenner,Richard K. G. Do,Richard K. G. Do,Alice P. Chen,Laura H. Tang,Laura H. Tang,David P. Kelsen,David P. Kelsen +27 more
TL;DR: The aims were to determine the safety, dose‐limiting toxicities (DLTs), maximum tolerated dose, and recommended phase 2 dose (RP2D) of veliparib combined with cisplatin and gemcitabine and to assess the antitumor efficacy and overall survival.
Journal ArticleDOI
Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Talia Golan,Tal Sella,Tal Sella,Eileen M. O'Reilly,Matthew H.G. Katz,Ron Epelbaum,David P. Kelsen,David P. Kelsen,Ayelet Borgida,Hannah Maynard,Hannah Maynard,Hedy L. Kindler,Eitan Friedmen,Milind Javle,Steven Gallinger +14 more
TL;DR: In this retrospective analysis, the prognosis of surgically resectable BRCA-associated PDAC is no different than that of sporadic PDAC from the same institution, and the role of platinum-based adjuvant therapy in this setting requires prospective investigation.